Sage Therapeutics (SAGE) ~45% Upside Does Not Nearly Reflect Potential Market Opportunity - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference
January 7, 2019 7:00 AM ESTMulti-franchise strategy ongoing in depression, neurology and neuropsychiatry
Commercial infrastructure build completed for ZULRESSO (brexanolone) injection ahead of March 19, 2019 target PDUFA date
Statistically significant results achieved in Phase 3 trial of SAGE-217 in postpartum depression
First patient dosed in second pivotal trial of SAGE-217 in major depressive disorder
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer,... More
